Clinical Trials Browser

Completed × Hodgkin Disease × Brentuximab Vedotin × Clear all

NCT01712490 2026-02-27

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Phase 3 Completed

1,334 enrolled 23 charts

Hodgkin Disease, Lymphoma

NCT02684292 2026-02-18

MK-3475-204

Phase 3 Completed

304 enrolled 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease

NCT02227199 2025-11-18

BV-ICE

Phase 1/2 Completed

45 enrolled 14 charts

Hodgkin Disease

NCT01508312 2025-10-21

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Completed

66 enrolled 14 charts

Hodgkin Disease

NCT02191930 2024-08-23

BVB

Phase 2 Completed

Hodgkin Disease

NCT01492088 2024-05-30

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Phase 1/2 Completed

36 enrolled 26 charts

Hodgkin Disease, Lymphoma, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT03013933 2024-02-22

Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1 Completed

Hodgkin Disease

NCT02398240 2023-10-26

Brentuximab for Newly Diagnosed Hodgkin Disease

Phase 2 Completed

Hodgkin Disease

NCT02572167 2022-11-08

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

93 enrolled 13 charts

Hodgkin Disease

NCT02292979 2022-08-19

BREACH

Phase 2 Completed

Hodgkin Disease

NCT03302728 2022-05-19

EpiBrentlen

Phase 1 Completed

DermatologicLymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02429375 2022-05-12

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

7 enrolled 10 charts

Hodgkin Disease, Recurrence

NCT01578967 2021-12-07

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Phase NA Completed

41 enrolled 14 charts

Hodgkin Disease

NCT02686346 2021-12-07

BV-ICE

Phase 1/2 Completed

Hodgkin Disease, Recurrence

NCT01780662 2021-10-28

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

46 enrolled 18 charts

Hodgkin Disease

NCT02298283 2021-07-26

BRAPP2

Phase 2 Completed

Hodgkin Disease

NCT01100502 2021-05-14

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Phase 3 Completed

329 enrolled 15 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma

NCT01990534 2021-04-09

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Phase 4 Completed

60 enrolled 21 charts

Hematologic Diseases, Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02939014 2021-02-24

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

Phase 2 Completed

39 enrolled 26 charts

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic

NCT02227433 2020-12-22

FIL_BVHD01

Phase 2 Completed

Hodgkin Disease

NCT02505269 2020-08-24

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

Phase 2 Completed

34 enrolled 7 charts

Hodgkin Disease

NCT01657331 2020-07-17

SGN+Benda

Phase 1/2 Completed

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic

NCT02164006 2019-10-02

Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

Phase 1 Completed

Hodgkin Disease

NCT02243436 2019-04-24

Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

Hodgkin Disease, Lymphoma

NCT01874054 2019-02-12

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Phase 1/2 Completed

55 enrolled 14 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma

NCT01569204 2018-10-29

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

Phase 2 Completed

Hodgkin Disease

NCT02567851 2018-05-11

BREVITY

Phase 2 Completed

Hodgkin Disease, Lymphoma

NCT01393717 2018-04-26

Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma

Phase 2 Completed

57 enrolled 14 charts

Hodgkin Disease

NCT01534078 2018-02-20

Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

Phase 2 Completed

34 enrolled 15 charts

Hodgkin Disease

NCT02244021 2018-02-09

BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV

Phase 2 Completed

Hodgkin Disease

NCT00947856 2017-02-02

A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

Phase 2 Completed

110 enrolled 15 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic

NCT01902160 2015-11-09

Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1 Completed

Hodgkin Disease

NCT00337194 2015-02-23

SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Completed

30 enrolled 13 charts

Hodgkin Disease

NCT00430846 2014-12-18

Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies

Phase 1 Completed

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic

NCT01026415 2014-12-18

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Phase 1 Completed

Carcinoma, Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Lymphoma, Large-Cell, Anaplastic

NCT01060904 2014-12-18

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Phase 1 Completed

Hematologic Diseases, Hodgkin Disease, Lymphoma

NCT01026233 2014-12-12

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

Phase 1 Completed

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic

NCT00051597 2011-10-12

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Phase 1/2 Completed

DermatologicLymphoidSarcoma

Hodgkin Disease, Sarcoma, Kaposi, Lymphoma, B-Cell, Lymphoma, T-Cell, Cutaneous, Dendritic Cell Sarcoma, Interdigitating